NA
EIGR

Neuburgh Advisers’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Neuburgh Advisers’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10
Closed -$3K – 924
2018
Q4 		$3K Buy
+10
New +$3.23K ﹤0.01% 892

Other funds holding EIGR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuburgh Advisers's EIGR Position: Q1 2019 in Review

Neuburgh Advisers sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2019, closing a stake of 10 shares — an estimated $3K sold.

Neuburgh Advisers first reported a position in EIGR in Q4 2018 and held it in 1 quarter. The position peaked at $3K in Q4 2018. 63 funds tracked by Wall St. Rank hold EIGR as of Q1 2019.

  • Neuburgh Advisers reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Neuburgh Advisers sold 10 Eiger BioPharmaceuticals, Inc. shares in Q1 2019, an estimated $3K.
  • Neuburgh Advisers first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2018 and held it in 1 quarter.
  • Neuburgh Advisers's Eiger BioPharmaceuticals, Inc. position peaked at $3K in Q4 2018.
  • 63 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2019.

Based on Neuburgh Advisers's 13F filing for Q1 2019, filed 13 May 2019.